

NEWSLETTER

APRIL 2022 | VOLUME 1 | ISSUE 1



<u>F</u>VIIa for <u>A</u>cute hemorrhagic <u>St</u>roke

Administered at <u>Earliest</u> <u>T</u>ime

Message from Dr. Broderick



We are excited to kick off the monthly FASTEST Newsletter as enrollment starts and sites are coming online. The FASTEST trial is critically important to find the first medical treatment

for spontaneous ICH. Recombinant Factor FVIIa is easy to mix up and administer but enrolling patients within 2 hours from last known well is a big challenge. However, we did this before in the NINDS tPA trial for acute ischemic stroke which changed stroke treatment throughout the world, and we have the opportunity to do this again. The newsletter will highlight our successes, challenges, and investigator teams throughout the world while also keeping our FASTEST investigators up-to-date with the latest science surrounding treatment of acute ICH.

Joseph Broderick, MD

Director NIH StrokeNet Director UC Gardner Neuroscience Institute

Issue Contents:

> Message from PI	Pg 1
> Webinar Invite	Pg 1
> Meet the Team	Pg 2
> Study Milstones	Pg 3
> Calender of Events	Pg 3
> FAQs	Pg 3
> Welcome to New Study sites	Pg 4
> First Site Randomizations	Pg 4
> Shout Outs	Pg 5
> Research Article of the Month	Pg 6
> Helpful Reminders	Pg 7
> Study Contacts & Info	Pg 7

Please join us for the FASTEST Monthly Webinar

Wednesday Aril 20th 2:00-3:00 pm EST


- ➤ Dr. Ritvij Bowry, MD from Memorial Hermann Hospital-Texas Medical Center will be discussing his study on ICH Enlargement.
- ➤ Patti Bratina, RN will shed light on how to leverage the MSU alert system via EMS to identify possible patients when the MSU isn't operating.

Zoom:

https://ucincinnati.zoom.us/j/96899791261?pwd=d1VtcEpp L0RoTkFxQTV1WW54SERaZz09

To join Zoom Meeting -- Meeting ID: 968 9979 1261 Passcode: 710245 or call in. To find your local number, go to https://ucincinnati.zoom.us/u/addjGYPaHx

Prior presentations and slides are available at, https://www.nihstrokenet.org/fastest/webinars



Protocol Investigators



Joseph Broderick, MD Protocol Director / Lead Principal Investigator (LPI) University of Cincinnati



James Grotta, MD
Memorial Hermann
Hospital Texas Medical
Center Houston



Andrew Naidech, MD, MSPH
Northwestern Memorial Hospital
Northwestern University
Chicago, IL



Jordan Elm, PhD Medical University of South Carolina Charleston, SC

NIH StrokeNet National Coordinating Center (NCC) - University of Cincinnati



Pooja Khatri, MD NCC PI University of Cincinnati



Julie Denlinger, BSN, RN
Prime Project Manager (PPM)
University of Cincinnati



Emily Stinson, MSNCC Project Manager
University of Cincinnati



Syed Quadri MDNCC Project Manager
University of Cincinnati

NCC Central Pharmacy



Noor Sabagha, PharmD, MPH NCC Central Pharmacy University of Cincinnati




Brittany Dornheggen CPhT II NCC Central Pharmacy University of Cincinnati



Chris Unger PharmD NCC Central Pharmacy University of Cincinnati



Kandis Harris Rhodes CphT NCC Central Pharmacy University of Cincinnati



StrokeNet National Data Management Center (NDMC) Medical University of South Carolina



Jocelyn Anderson, MPHWebDCU™ Data Manager
Medical University of South Carolina



Jama Olsen, MPAStrokeNet NDMC Site Monitoring Manager
Medical University of South Carolina



Evan Tomaschek, RN, MPHFASTEST Trial WebDCU™ Data Manager
Medical University of South Carolina

FASTEST Imaging Core Lab (ICL)



Lily Wang, MD, MPHFASTEST Imaging Core
University of Cincinnati



Janice Carrozzella, MSN, CNP, RT(R), CCRA FASTEST Imaging Core University of Cincinnati



FASTEST International Investigators



Darisuh Dowlatshahi, MD, PhD
The Ottawa Hospital
Ottawa Hospital Research Institute
University of Ottawa



Philip Bath, MD

Nottingham City Hospital

Head, Division of Clinical Neuroscience
University of Nottingham



Thorsten Steiner, MD, PhD Frankfurt Höchst, Germany. Klinikum Frankfurt Hoechst and Heidelberg University Hospital



Carlos Molina, MD Hospital Universitari Vall d'Hebron Barcelona, Spain



Kazunori Toyoda, MD, PhDNational Cerebral and Cardiovascular Center
Osaka, Japan

FASTEST International CROs



Joanne Lambley
Canadian CRO Collaborator
Ottawa Hospital Research Institute
University of Ottawa, Canada



Mayumi Fukuda-Doi, MD, MPH
Japanese CRO Collaborator
National Cerebral and Cardiovascular Center
Osaka, Japan



Diana Salein, MD, PhDEU/UK CRO Collaborator
Research Coordinating Center
Europe



Sohei YOSHIMURA, MD, MPHJapanese CRO Collaborator
National Cerebral and Cardiovascular Center
Osaka, Japan



Megumi HatanoJapanese CRO Collaborator
National Cerebral and Cardiovascular Center
Osaka, Japan

Total Sites Released to Enroll: 10 (6 USA, 2 Germany, 1 Japan, 1 Canadian)

Total Randomization = 7

- US Randomizations: 5.
- International randomizations: 2 (2 Canadian)

Randomization this month = 1

Total Screen Failures = 20

Subjects Randomized by MSU = 0

Subjects Terminated Early = $\mathbf{0}$

eConsent Used = 0

Remote Consent Used = 0

CALENDAR OF EVENTS

Upcoming Advarra EFIC Panel meeting dates - April 11th and 25th May 9th and 23rd

Upcoming FASTEST Monthly Webinar: Wednesday Aril 20th 2:00-3:00 pm EST



Q: Who do I reach out to if I have questions about EFIC?

A: Please reach out to FASTEST Project Manager Emily Stinson at stinsoey@ucmail.uc.edu or Julie Denlinger Denlinger at denlinjk@ucmail.uc.edu

Q: Who can help me if I have questions about the Advarra CIRBI application?

A: Please reach out to Advarra service support representative Kyle Naylor at Kyle.Naylor@advarra.com

Q: If I have questions about the FASTEST Informed Consent template who can help me?

A: For US sites please reach out to FASTEST Project Manager Emily Stinson stinsoey@ucmail.uc.edu or Advarra FASTEST service representative Kyle Naylor Kyle.Naylor@advarra.com. For OUS sites please reach out to your FASTEST CRO representative or FASTEST Project Manager Julie Denlinger denlinjk@ucmail.uc.edu

Q: Who at my site is required to do imaging training and who can help me if I have questions about the FASTEST required Imaging Training?

A: Certification is required for investigators and sub investigators who will determine eligibility as a responsibility on the DOA. Please reach out to Julie Denlinger <u>denlinjk@ucmail.uc.edu</u> if you have questions or need assistance with this training.

New Sites... Welcome Aboard!

The following new sites were **released to enroll** in the FASTEST study during the month of April



Grady Memorial Hospital, Atlanta, GA

Site PI: Digvijaya Navalkele, M.D., MPH





National Cerebral and Cardiovascular Center, Osaka, Japan



Congratulations on First Enrollment!



University of Cincinnati Medical Center Team

PSC: Stephanie Thomas Site PI: Joseph Broderick, MD Pooja Khatri MD



UC San Diego Medical Center, Hillcrest Team

PSC: Karen Rapp, R.N., B.S.N., C.C.R.C. & TERI McQuaid Site PI: Thomas M. Hemmen, M.D., Ph.D. Brett Meyer, MD Congratulations to all our US sites that have completed their EFIC reports and gained Advarra full study approval. Advarra shared that the FASTEST sites reviewed have been strong! Well done!

Recently, two of our US sites, received extra recognition for their EFIC community consultation efforts from Advarra. We would like to extend a special acknowledgment to the teams at <u>UC Irvine (UCI)</u>, under **Dr. Shah** and **PSC Julia Fong** and <u>Kaiser Permanente Los Angeles Medical Center</u>, under **Dr. Sangha** and **PSC Vanessa Audea**. The Advarra reviewer described both sites' efforts as "excellent". **AMAZING WORK!**

Thank you to the sites preparing for readiness:

- Kaiser Permanente
- Central DuPage
- VCU

Thank you to sites that have submitted to Advarra for CIRB review:

Northwestern

Thank you to sites that have competed EFIC Plans and preparing to begin EFIC activities:

- Thomas Jefferson
- Mass General
- Regions

Thank you for sites preparing for Advarra submission:

- UMASS
- Stony Brook NY
- North Shore





Top Enrolling Site

Congratulations to **Memorial Hermann Hospital-Texas Medical Center** for being the highest enrolling site in the study.

Subjects enrolled = 3!!

Congratulations to the Enrolling Sites This Month!

1. Memorial Hermann Hospital Texas Medical Center

2 Subjects

RESEARCH ARTICLE OF THE MONTH

Hemorrhage Enlargement Is More Frequent in the First 2 Hours: A Prehospital Mobile Stroke Unit Study

Ritvij Bowry, Stephanie A. Parker, Patti Bratina, Noopur Singh, Jose-Miguel Yamal, Suja S. Rajan, Asha P. Jacob, Kenny Phan, Alexandra Czap and James C. Grotta

Originally published4 Apr 2022 / https://doi.org/10.1161/STROKEAHA.121.037591 / Stroke.2022;0:STROKEAHA.121.037591

Background: Hematoma enlargement (HE) after intracerebral hemorrhage (ICH) is a therapeutic target for improving outcomes. Hemostatic therapies to prevent HE may be more effective the earlier they are attempted. An understanding of HE in first 1 to 2 hours specifically in the prehospital setting would help guide future treatment interventions in this time frame and setting.

Methods: Patients with spontaneous ICH within 4 hours of symptom onset were prospectively evaluated between May 2014 and April 2020 as a prespecified substudy within a multicenter trial of prehospital mobile stroke unit versus standard management. Baseline computed tomography scans obtained <1, 1 to 2, and 2 to 4 hours postsymptom onset on the mobile stroke unit in the prehospital setting were compared with computed tomography scans repeated 1 hour later and at 24 hours in the hospital. HE was defined as >6 mL if baseline ICH volume was <20 mL and 33% increase if baseline volume >20 mL. The association between time from symptom onset to baseline computed tomography (hours) and HE was investigated using Wilcoxon rank-sum test when time was treated as a continuous variable and using Fisher exact test when time was categorized. Kruskal-Wallis and Wilcoxon rank-sum tests evaluated differences in baseline volumes and HE. Univariable and multivariable logistic regression analyses were conducted to identify factors associated with HE and variable selection was performed using cross-validated L1regularized (Lasso regression). This study adhered to STROBE guidelines (Strengthening the Reporting of Observational Studies in Epidemiology) for cohort studies.

Results: One hundred thirty-nine patients were included. There was no difference between baseline ICH volumes obtained <1 hour (n=43) versus 1 to 2 hour (n=51) versus >2 hours (n=45) from symptom onset (median [interquartile range], 13 mL [6-24] versus 14 mL [6-30] versus 12 mL [4-19]; P=0.65). However, within the same 3 time epochs, initial hematoma growth (volume/time from onset) was greater with earlier baseline scanning (median [interquartile range], 17 mL/hour [9-35] versus 9 mL/hour [5-23]) versus 4 mL/hour [2-7]; P<0.001). Forty-nine patients had repeat scans 1 hour after baseline imaging

(median, 2.3 hours [interquartile range. 1.9-3.1] after symptom onset). Eight patients (16%) had HE during that 1-hour interval; all of these occurred in patients with baseline imaging within 2 hours of onset (5/18=28% with baseline imaging within 1 hour, 3/18=17% within 1-2 hour, 0/13=0% > 2 hours; P=0.02). HE did not occur between the scans repeated at 1 hour and 24 hours. No association between baseline variables and HE was detected in multivariable analyses.

Conclusions: HE in the next hour occurs in 28% of ICH patients with baseline imaging within the first hour after symptom onset, and in 17% of those with baseline imaging between 1 and 2 hours. These patients would be a target for ultraearly hemostatic intervention.

Hemorrhage enlargement is more frequent in the first two hours:

A Pre-hospital Mobile Stroke Unit Study



Reducing hematoma enlargement after ICH can improve outcomes





Earlier identification of hematoma enlargement could help guide earlier treatment



Patients with spontaneous ICH within 4 hours of symptom onset were evaluated on a mobile stroke unit in the <u>pre-hospital</u> setting

Baseline CT scans obtained within <1, 1-2 and 2-4 hours after symptoms were compared with CT scans repeated 1 hour later



Early hematoma growth was greater within 2 hours of symptom onset

28% patients within 1 hour of symptoms

" 17% patients between 1-2 hours

Patient with ICH within 2 hours would be a target for ultra-early hemostatic interventions

HELPFUL REMINDERS & TIPS

For Project Managers and Study Teams

- ➤ HELPFUL Tip We would like to share a few of the tactics **UC Irvine** used, that proved very successful in canvassing deep into their community and reaching key demographic communities. UCI worked with their Public Health division, that had great penetration and contacts into the community. They reached community members using a variety of media, print and radio, and in a variety of languages. The team went to community markets and events to meet and talk to community members. Their efforts embodied the goals of EFIC to inform the community and allow the community to dialog with the team. We would be happy to share their examples with other sites. **Sites can view EFIC events, from other sites, in WebDCU, and can generate ideas for your own community events!**
- ➤ As you are completing EFIC events, please complete the CC and PD forms in WebDCU[™]. The updated EFIC Forms Resource Guide is available in WebDCU[™] (in the Toolbox under Project Documents) and is a very helpful tool for completing these forms. The FASTEST webinar from March 16th, 2021 (available at https://www.nihstrokenet.org/fastest/webinars) can provide additional tips. If you have questions in completing the forms, please feel free to reach out to the NCC. The NCC is also happy to review the forms and provide guidance and feedback along the way to ensure completeness.
- ➤ **US Manual of Procedures v1:** Finalized version of the US MOP v1 has been distributed to all the sites but can also be found in the WebDCU Tool Box: https://webdcu.musc.edu/nett/ViewRecord.asp?theFormID=1015&theRecordID=109

From the **FASTEST** Central Pharmacy Team

- > Study Drug Shipment: The Central Pharmacy will ship FASTEST study drugs few days prior to the readiness call. FASTEST IP will be shipped refrigerated. The initial study drug shipment will contain a total of two study drug kits to sites with one enrolling location (ED or MSU) and four study drug kits to sites that have two enrolling locations (ED+MSU) or 2 Eds
- For the US sites: Please upload the following regulatory documents into WebDCU for your site pharmacy to receive IP:
 - Institutional Pharmacy License
 - Institutional Drug Destruction Policy/SOP
 - Clinical Site Drug Shipping Address, Phone Number, and Contact Person
 - Adding Pharmacy Personnel to WebDCU DOA

STUDY CONTACTS & USEFUL INFO

For any study related queries or help please reach out to **FASTEST** Project managers

International Sites: Julie Denlinger (denlinjk@ucmail.uc.edu)
United States Sites: Emily Stinson (stinsoey@ucmail.uc.edu)

Syed Quadri (quadrisd@ucmail.uc.edu)

For more information regarding the **FASTES** study please visit: https://www.nihstrokenet.org/fastest/home

For prior FASTES Presentations and Webinars slides and recordings visit: https://www.nihstrokenet.org/fastest/webinars

For more information regarding the StrokeNet Trials please visit: https://www.nihstrokenet.org/

